Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
3
Story being shared
Major pharma eyes mid-priced biotech M&A deals in 2013
Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately.
Xconomy/San Francisco (1/10)
Or we can send an email on your behalf